Trial Profile
A phase II multi-center study to evaluate the efficacy and safety of 500mg fulvestrant (Faslodex) as a first-line hormonal treatment in postmenopausal women with hormone receptor-positive metastatic breast cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2007
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 20 Apr 2007 New trial record.